AMAC Supports Bill to Study PBM Business Practices

Among other provisions, this bill would direct the Federal Trade Commission (FTC) to launch a study and report to Congress on the effects pharmacy benefit manager (PBM) consolidation has on the competitive landscape of the prescription drug supply chain. The study would also examine whether PBMs steer patients to pharmacies in which they have an ownership stake and use formulary designs to depress the market share of low-cost, lower-rebate prescription drugs.


Read the full letter >